{"pmid":32459663,"title":"COVID-19, microangiopathy, hemostatic activation, and complement.","text":["COVID-19, microangiopathy, hemostatic activation, and complement.","In COVID-19, complement activation may contribute to hemostatic activation leading to pathological features such as microvascular injury and coagulopathy.","J Clin Invest","Song, Wen-Chao","FitzGerald, Garret A","32459663"],"abstract":["In COVID-19, complement activation may contribute to hemostatic activation leading to pathological features such as microvascular injury and coagulopathy."],"journal":"J Clin Invest","authors":["Song, Wen-Chao","FitzGerald, Garret A"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459663","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1172/JCI140183","topics":["Mechanism","Treatment"],"weight":1,"_version_":1667967698973229057,"score":9.490897,"similar":[{"pmid":32461141,"title":"The case of Complement activation in COVID-19 multiorgan impact.","text":["The case of Complement activation in COVID-19 multiorgan impact.","The novel coronavirus disease COVID-19 originates in the lungs, but may extend to other organs, causing, in severe cases, multiorgan damage, including cardiac injury and acute kidney injury. In severe cases, the presence of kidney injury is associated with increased risk of death, highlighting the relevance of this organ as a target of SARS-CoV-2 infection. COVID-19-associated tissue injury is not primarily mediated by viral infection, but rather is a result of the inflammatory host immune response, which drives hypercytokinemia and aggressive inflammation that affect lung parenchymal cells, diminishing oxygen uptake but also endothelial cells, resulting in endotheliitis and thrombotic events and intravascular coagulation. The complement system represents the first response of the host immune system to SARS-CoV-2 infection, but there is growing evidence that unrestrained activation of complement induced by the virus in the lungs and other organs plays a major role in acute and chronic inflammation, endothelial cell dysfunction, thrombus formation and intravascular coagulation, and ultimately contributes to multiple organ failure and death. In this review we will discuss the relative role of the different complement activation products in the pathogenesis of COVID-19-associated tissue inflammation and thrombosis and propose the hypothesis that blockade of the terminal complement pathway may represent a potential therapeutic option for the prevention and treatment of lung and multi-organ damage.","Kidney Int","Noris, Marina","Benigni, Ariela","Remuzzi, Giuseppe","32461141"],"abstract":["The novel coronavirus disease COVID-19 originates in the lungs, but may extend to other organs, causing, in severe cases, multiorgan damage, including cardiac injury and acute kidney injury. In severe cases, the presence of kidney injury is associated with increased risk of death, highlighting the relevance of this organ as a target of SARS-CoV-2 infection. COVID-19-associated tissue injury is not primarily mediated by viral infection, but rather is a result of the inflammatory host immune response, which drives hypercytokinemia and aggressive inflammation that affect lung parenchymal cells, diminishing oxygen uptake but also endothelial cells, resulting in endotheliitis and thrombotic events and intravascular coagulation. The complement system represents the first response of the host immune system to SARS-CoV-2 infection, but there is growing evidence that unrestrained activation of complement induced by the virus in the lungs and other organs plays a major role in acute and chronic inflammation, endothelial cell dysfunction, thrombus formation and intravascular coagulation, and ultimately contributes to multiple organ failure and death. In this review we will discuss the relative role of the different complement activation products in the pathogenesis of COVID-19-associated tissue inflammation and thrombosis and propose the hypothesis that blockade of the terminal complement pathway may represent a potential therapeutic option for the prevention and treatment of lung and multi-organ damage."],"journal":"Kidney Int","authors":["Noris, Marina","Benigni, Ariela","Remuzzi, Giuseppe"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461141","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.kint.2020.05.013","keywords":["c5 inhibition","covid-19","complement activation","complement terminal pathway","kidney injury","vascular injury"],"locations":["multiorgan"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1668079521362870273,"score":140.09827},{"pmid":32369610,"title":"Severe COVID-19 infection and thrombotic microangiopathy: success doesn't come easily.","text":["Severe COVID-19 infection and thrombotic microangiopathy: success doesn't come easily.","Recent evidence suggests that signs and symptoms of severe COVID-19 infection resemble more the pathophysiology and phenotype of complement-mediated thrombotic micoangiopathies (TMA), rather than sepsis-induced coagulopathy or disseminated intravascular coagulation (DIC) (Campbell and Kahwash 2020, Zhang, et al 2020). Since effective treatment is available for complement-mediated TMA (Gavriilaki 2020), we aim to systematically describe relevant features (clinical phenotype, pathophysiology and management) in patients with severe COVID-19 infection.","Br J Haematol","Gavriilaki, Eleni","Brodsky, Robert Alan","32369610"],"abstract":["Recent evidence suggests that signs and symptoms of severe COVID-19 infection resemble more the pathophysiology and phenotype of complement-mediated thrombotic micoangiopathies (TMA), rather than sepsis-induced coagulopathy or disseminated intravascular coagulation (DIC) (Campbell and Kahwash 2020, Zhang, et al 2020). Since effective treatment is available for complement-mediated TMA (Gavriilaki 2020), we aim to systematically describe relevant features (clinical phenotype, pathophysiology and management) in patients with severe COVID-19 infection."],"journal":"Br J Haematol","authors":["Gavriilaki, Eleni","Brodsky, Robert Alan"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32369610","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16783","keywords":["covid-19","complement","complement inhibition","thrombotic microangiopathy"],"topics":["Diagnosis","Mechanism","Treatment"],"weight":1,"_version_":1666138496204537856,"score":133.53319},{"pmid":32361635,"pmcid":"PMC7195270","title":"Analysis of complement deposition and viral RNA in placentas of COVID-19 patients.","text":["Analysis of complement deposition and viral RNA in placentas of COVID-19 patients.","COVID-19, the disease caused by the novel Coronavirus, SARS-CoV-2, is increasingly being recognized as a systemic thrombotic and microvascular injury syndrome that may have its roots in complement activation. We had the opportunity to study the placental pathology of five full-term births to COVID-19 patients. All five exhibited histology indicative of fetal vascular malperfusion characterized by focal avascular villi and thrombi in larger fetal vessels. Vascular complement deposition in the placentas was not abnormal, and staining for viral RNA and viral spike protein was negative. While all cases resulted in healthy, term deliveries, these findings indicate the systemic nature of COVID-19 infection. The finding of vascular thrombosis without complement deposition may reflect the systemic nature of COVID-19's procoagulant effects unrelated to systemic complement activation.","Ann Diagn Pathol","Mulvey, J Justin","Magro, Cynthia M","Ma, Lucy X","Nuovo, Gerard J","Baergen, Rebecca N","32361635"],"abstract":["COVID-19, the disease caused by the novel Coronavirus, SARS-CoV-2, is increasingly being recognized as a systemic thrombotic and microvascular injury syndrome that may have its roots in complement activation. We had the opportunity to study the placental pathology of five full-term births to COVID-19 patients. All five exhibited histology indicative of fetal vascular malperfusion characterized by focal avascular villi and thrombi in larger fetal vessels. Vascular complement deposition in the placentas was not abnormal, and staining for viral RNA and viral spike protein was negative. While all cases resulted in healthy, term deliveries, these findings indicate the systemic nature of COVID-19 infection. The finding of vascular thrombosis without complement deposition may reflect the systemic nature of COVID-19's procoagulant effects unrelated to systemic complement activation."],"journal":"Ann Diagn Pathol","authors":["Mulvey, J Justin","Magro, Cynthia M","Ma, Lucy X","Nuovo, Gerard J","Baergen, Rebecca N"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361635","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.anndiagpath.2020.151529","topics":["Case Report"],"weight":1,"_version_":1666138495509331968,"score":130.49574},{"pmid":32387855,"title":"Analysis of complement deposition and viral RNA in placentas of COVID-19 patients.","text":["Analysis of complement deposition and viral RNA in placentas of COVID-19 patients.","COVID-19, the disease caused by the novel Coronavirus, SARS-CoV-2, is increasingly being recognized as a systemic thrombotic and microvascular injury syndrome that may have its roots in complement activation. We had the opportunity to study the placental pathology of five full-term births to COVID-19 patients. All five exhibited histology indicative of fetal vascular malperfusion characterized by focal avascular villi and thrombi in larger fetal vessels. Vascular complement deposition in the placentas was not abnormal, and staining for viral RNA and viral spike protein was negative. While all cases resulted in healthy, term deliveries, these findings indicate the systemic nature of COVID-19 infection. The finding of vascular thrombosis without complement deposition may reflect the systemic nature of COVID-19's procoagulant effects unrelated to systemic complement activation.","Ann Diagn Pathol","Mulvey, J Justin","Magro, Cynthia M","Ma, Lucy X","Nuovo, Gerard J","Baergen, Rebecca N","32387855"],"abstract":["COVID-19, the disease caused by the novel Coronavirus, SARS-CoV-2, is increasingly being recognized as a systemic thrombotic and microvascular injury syndrome that may have its roots in complement activation. We had the opportunity to study the placental pathology of five full-term births to COVID-19 patients. All five exhibited histology indicative of fetal vascular malperfusion characterized by focal avascular villi and thrombi in larger fetal vessels. Vascular complement deposition in the placentas was not abnormal, and staining for viral RNA and viral spike protein was negative. While all cases resulted in healthy, term deliveries, these findings indicate the systemic nature of COVID-19 infection. The finding of vascular thrombosis without complement deposition may reflect the systemic nature of COVID-19's procoagulant effects unrelated to systemic complement activation."],"journal":"Ann Diagn Pathol","authors":["Mulvey, J Justin","Magro, Cynthia M","Ma, Lucy X","Nuovo, Gerard J","Baergen, Rebecca N"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387855","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.anndiagpath.2020.151530","topics":["Case Report"],"weight":1,"_version_":1666428892597977088,"score":130.49574},{"pmid":32456506,"title":"Hemostatic laboratory derangements in COVID-19 with a focus on platelet count.","text":["Hemostatic laboratory derangements in COVID-19 with a focus on platelet count.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease in 2019 (COVID-19) which rapidly evolved from an outbreak in Wuhan, China into a pandemic that has resulted in over millions of infections and over hundreds of thousands of mortalities worldwide. Various coagulopathies have been reported in association with COVID-19, including disseminated intravascular coagulation (DIC), sepsis-induced coagulopathy (SIC), local microthrombi, venous thromboembolism (VTE), arterial thrombotic complications, and thrombo-inflammation. There is a plethora of publications and conflicting data on hematological and hemostatic derangements in COVID-19 with some data suggesting the link to disease progress, severity and/or mortality. There is also growing evidence of potentially useful clinical biomarkers to predict COVID-19 progression and disease outcomes. Of those, a link between thrombocytopenia and COVID-19 severity or mortality was suggested. In this opinion report, we examine the published evidence of hematological and hemostatic laboratory derangements in COVID-19 and the interrelated SARS-CoV-2 induced inflammation, with a focussed discussion on platelet count alterations. We explore whether thrombocytopenia could be a potential disease biomarker and we provide recommendations for future studies in this regard.","Platelets","Amgalan, Ariunzaya","Othman, Maha","32456506"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease in 2019 (COVID-19) which rapidly evolved from an outbreak in Wuhan, China into a pandemic that has resulted in over millions of infections and over hundreds of thousands of mortalities worldwide. Various coagulopathies have been reported in association with COVID-19, including disseminated intravascular coagulation (DIC), sepsis-induced coagulopathy (SIC), local microthrombi, venous thromboembolism (VTE), arterial thrombotic complications, and thrombo-inflammation. There is a plethora of publications and conflicting data on hematological and hemostatic derangements in COVID-19 with some data suggesting the link to disease progress, severity and/or mortality. There is also growing evidence of potentially useful clinical biomarkers to predict COVID-19 progression and disease outcomes. Of those, a link between thrombocytopenia and COVID-19 severity or mortality was suggested. In this opinion report, we examine the published evidence of hematological and hemostatic laboratory derangements in COVID-19 and the interrelated SARS-CoV-2 induced inflammation, with a focussed discussion on platelet count alterations. We explore whether thrombocytopenia could be a potential disease biomarker and we provide recommendations for future studies in this regard."],"journal":"Platelets","authors":["Amgalan, Ariunzaya","Othman, Maha"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32456506","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/09537104.2020.1768523","keywords":["covid","sars-cov-2","platelets","thrombocytopenia","thromboinflammation"],"locations":["Wuhan","China","thrombocytopenia","thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1668141322605690881,"score":130.30672}]}